



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 4, 2016

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

Dear Sirs,

**Sub: Press Release**

Please find enclosed press release for the financial results for the second quarter and half year ended September 30, 2016.

Please take the above on record.

Thanking you,

Yours truly,  
For Pfizer Limited

**Prajeet Nair**  
Company Secretary

Encl: A/a



**Press Release  
For immediate dissemination**

**Pfizer Limited Revenues at Rs 552 crore, increase by 5%, for the quarter ended September 30, 2016.**

Pfizer Limited announced its results for the quarter and half year ended September 30, 2016.

**Revenues**

Revenues for the quarter ended September 30, 2016 is Rs. 552 crores as compared to Rs. 525 crores in the same period last year, reflecting a growth of 5%.

Revenue for the half year ended September 30, 2016 is Rs. 1066 crores as compared to Rs. 1022 crores in the same period last year, reflecting a growth of 4%.

This quarter witnessed the full impact of the price reductions announced by the Government between March and June of this year. Revenue has been impacted by Rs. 22 crores due to these price reductions with the impact being felt most in mid-tier and tail brands. Excluding the impact of price reductions, revenue growth for the quarter would have been 9%.

**Profits before other income, exceptional items and tax**

Profit from operations (before other income, exceptional items and tax) for the quarter and half year is Rs. 75 crores and Rs. 161 crores respectively, primarily impacted by pricing policy.

**Exceptional items**

During the quarter under review, the Company on completion of requisite formalities and receipt of necessary regulatory approvals has concluded the transfer of four brands for a consideration of Rs. 110 crores. The consideration net of direct expenses and adjustment for proportionate allocation of fair value of consideration has been reflected as an Exceptional item.

## **Profit after tax**

Net Profit after tax (including other comprehensive income) for the quarter is Rs. 126 crores as against Rs. 83 crores in the same period last year, reflecting a growth of 52%.

Net Profit after tax (including other comprehensive income) for the half year is Rs. 206 crores as against Rs. 158 crores in the same period last year, reflecting a growth of 31%.

For more information,

### **Investors:**

**Prajeet Nair**

Pfizer Limited

Ph.: +91-22-66932352

Email: [prajeet.nair@pfizer.com](mailto:prajeet.nair@pfizer.com)

### **Media:**

**Saritha Rajeev Hajare**

Pfizer Limited

+ 91 9619990917

[saritha.r.hajare@pfizer.com](mailto:saritha.r.hajare@pfizer.com)

### **About Pfizer Limited:**

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at [www.pfizerindia.com](http://www.pfizerindia.com)

### **Disclaimer**

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.